BR112013024801A2 - formulações de otamixaban com estabilidade aprimorada - Google Patents
formulações de otamixaban com estabilidade aprimoradaInfo
- Publication number
- BR112013024801A2 BR112013024801A2 BR112013024801A BR112013024801A BR112013024801A2 BR 112013024801 A2 BR112013024801 A2 BR 112013024801A2 BR 112013024801 A BR112013024801 A BR 112013024801A BR 112013024801 A BR112013024801 A BR 112013024801A BR 112013024801 A2 BR112013024801 A2 BR 112013024801A2
- Authority
- BR
- Brazil
- Prior art keywords
- otamixaban
- formulations
- improved stability
- amino
- methyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 2
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 title abstract 2
- 229950009478 otamixaban Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940123583 Factor Xa inhibitor Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305347 | 2011-03-29 | ||
| US201161499941P | 2011-06-22 | 2011-06-22 | |
| PCT/EP2012/055361 WO2012130819A1 (en) | 2011-03-29 | 2012-03-27 | Otamixaban formulations with improved stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013024801A2 true BR112013024801A2 (pt) | 2016-12-20 |
Family
ID=44584895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013024801A BR112013024801A2 (pt) | 2011-03-29 | 2012-03-27 | formulações de otamixaban com estabilidade aprimorada |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20140018398A1 (enExample) |
| EP (1) | EP2691075A1 (enExample) |
| JP (1) | JP5993933B2 (enExample) |
| KR (1) | KR101844623B1 (enExample) |
| CN (1) | CN103561723B (enExample) |
| AR (1) | AR085580A1 (enExample) |
| AU (1) | AU2012234323A1 (enExample) |
| BR (1) | BR112013024801A2 (enExample) |
| CA (1) | CA2830962C (enExample) |
| CO (1) | CO6801755A2 (enExample) |
| EA (1) | EA025572B1 (enExample) |
| IL (1) | IL228573A (enExample) |
| MA (1) | MA35050B1 (enExample) |
| MX (1) | MX342324B (enExample) |
| PH (1) | PH12013501991A1 (enExample) |
| SG (1) | SG193932A1 (enExample) |
| UY (1) | UY33975A (enExample) |
| WO (1) | WO2012130819A1 (enExample) |
| ZA (1) | ZA201308061B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012234323A1 (en) | 2011-03-29 | 2013-10-17 | Sanofi | Otamixaban formulations with improved stability |
| PL2953931T3 (pl) | 2013-01-31 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | Pirydonoamidy jako modulatory kanałów sodowych |
| DE102013212933B3 (de) * | 2013-07-03 | 2014-11-27 | Schaeffler Technologies Gmbh & Co. Kg | Lageranordnung in einem Elektromotor |
| EP3668516B1 (en) | 2017-08-16 | 2021-09-22 | Merck Patent GmbH | Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid and a dicarboxylic acid |
| CN109010273B (zh) * | 2018-10-08 | 2021-03-19 | 中国药科大学 | 一种阿哌沙班纳米混悬剂及其制备方法 |
| CN113384526A (zh) * | 2021-08-03 | 2021-09-14 | 合肥医工医药股份有限公司 | 一种稳定的阿哌沙班口服溶液制剂及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3030272A (en) * | 1960-05-26 | 1962-04-17 | Abbott Lab | Stable heaparin solution |
| CA2149150C (en) | 1992-11-27 | 2000-08-01 | David R. Carver | Injectable taxol composition with improved stability |
| IL125163A0 (en) | 1996-01-02 | 1999-01-26 | Rhone Poulenc Rorer Pharma | Substituted n-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides |
| US6080767A (en) | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| GB0108903D0 (en) * | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
| US20050059719A1 (en) * | 2003-09-16 | 2005-03-17 | Badawy Sherif Ibrahim Farag | Solid dosage formulation containing a Factor Xa inhibitor and method |
| FR2863891B1 (fr) * | 2003-12-23 | 2006-03-24 | Pf Medicament | Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation |
| AU2010277725B2 (en) * | 2009-07-29 | 2016-08-18 | Sanofi | Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients |
| PT2691371E (pt) | 2011-03-29 | 2015-07-20 | Sanofi Sa | Sal de ácido benzóico de otamixaban |
| AU2012234323A1 (en) | 2011-03-29 | 2013-10-17 | Sanofi | Otamixaban formulations with improved stability |
-
2012
- 2012-03-27 AU AU2012234323A patent/AU2012234323A1/en not_active Abandoned
- 2012-03-27 EP EP12710516.1A patent/EP2691075A1/en not_active Withdrawn
- 2012-03-27 CN CN201280026572.6A patent/CN103561723B/zh not_active Expired - Fee Related
- 2012-03-27 BR BR112013024801A patent/BR112013024801A2/pt not_active Application Discontinuation
- 2012-03-27 US US14/008,343 patent/US20140018398A1/en not_active Abandoned
- 2012-03-27 MA MA36345A patent/MA35050B1/fr unknown
- 2012-03-27 EA EA201391406A patent/EA025572B1/ru not_active IP Right Cessation
- 2012-03-27 UY UY0001033975A patent/UY33975A/es not_active Application Discontinuation
- 2012-03-27 JP JP2014501567A patent/JP5993933B2/ja not_active Expired - Fee Related
- 2012-03-27 SG SG2013071352A patent/SG193932A1/en unknown
- 2012-03-27 CA CA2830962A patent/CA2830962C/en not_active Expired - Fee Related
- 2012-03-27 MX MX2013011260A patent/MX342324B/es active IP Right Grant
- 2012-03-27 US US13/431,571 patent/US20120252852A1/en not_active Abandoned
- 2012-03-27 AR ARP120101016A patent/AR085580A1/es unknown
- 2012-03-27 KR KR1020137028419A patent/KR101844623B1/ko not_active Expired - Fee Related
- 2012-03-27 WO PCT/EP2012/055361 patent/WO2012130819A1/en not_active Ceased
- 2012-03-27 PH PH1/2013/501991A patent/PH12013501991A1/en unknown
-
2013
- 2013-09-29 IL IL228573A patent/IL228573A/en active IP Right Grant
- 2013-10-23 CO CO13251310A patent/CO6801755A2/es unknown
- 2013-10-29 ZA ZA2013/08061A patent/ZA201308061B/en unknown
-
2016
- 2016-09-14 US US15/265,191 patent/US9993464B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| UY33975A (es) | 2012-10-31 |
| US20140018398A1 (en) | 2014-01-16 |
| IL228573A0 (en) | 2013-12-31 |
| EA025572B1 (ru) | 2017-01-30 |
| JP2014509621A (ja) | 2014-04-21 |
| US20120252852A1 (en) | 2012-10-04 |
| AU2012234323A1 (en) | 2013-10-17 |
| CN103561723A (zh) | 2014-02-05 |
| AR085580A1 (es) | 2013-10-09 |
| JP5993933B2 (ja) | 2016-09-14 |
| CA2830962C (en) | 2019-06-18 |
| NZ616180A (en) | 2015-10-30 |
| US9993464B2 (en) | 2018-06-12 |
| EP2691075A1 (en) | 2014-02-05 |
| EA201391406A1 (ru) | 2014-02-28 |
| WO2012130819A1 (en) | 2012-10-04 |
| MA35050B1 (fr) | 2014-04-03 |
| MX2013011260A (es) | 2014-03-27 |
| US20170224668A1 (en) | 2017-08-10 |
| KR20140019818A (ko) | 2014-02-17 |
| PH12013501991A1 (en) | 2013-11-25 |
| IL228573A (en) | 2017-12-31 |
| CA2830962A1 (en) | 2012-10-04 |
| CO6801755A2 (es) | 2013-11-29 |
| KR101844623B1 (ko) | 2018-04-02 |
| MX342324B (es) | 2016-09-23 |
| CN103561723B (zh) | 2016-04-20 |
| ZA201308061B (en) | 2015-01-28 |
| SG193932A1 (en) | 2013-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY32062A (es) | Inhibidores de beta-secretasa | |
| EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
| BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
| BR112014009146A2 (pt) | formulações de etanercepte estabilizadas com aminoácidos | |
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| BR112012008889A2 (pt) | compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes | |
| NI201100081A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes. | |
| MY183588A (en) | New salvianolic acid compound l, preparation method and use thereof | |
| BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
| BR112012009376B8 (pt) | composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica | |
| EA201391720A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| PH12015501678A1 (en) | Inhibitors of influenza viruses replication | |
| CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
| BRPI0821994B8 (pt) | composto ou um enantiômero, um diasteroisômero ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto | |
| MX2012015097A (es) | Derivados de acido naft-2-ilacetico para tratar sida. | |
| BRPI0906444B8 (pt) | compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos | |
| BR112014006297A2 (pt) | inibidores de n-[1-ciano-2-(fenil) etil]-2-azabiciclo [2.2.1] heptano-3-carboxamida de catepsina c, seus usos, e composição farmacêutica | |
| GT201200158A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
| BR112013024801A2 (pt) | formulações de otamixaban com estabilidade aprimorada | |
| EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
| BR112015008297A2 (pt) | antagonistas de mglu2/3 para o tratamento de distúrbios autistas | |
| UA111357C2 (uk) | Аналоги епоксіейкозатриєнової кислоти, композиція на їх основі, застосування для лікування захворювань та спосіб зниження гіпертонії та нефротоксичності (варіанти) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |